托拉塞米治疗慢性心力衰竭的临床观察

摘要

OBJECTIVE:To observe clinical efficacy and safety of torasemide in the treatment of chronic heart failure(CHF). METHODS:94 patients with CHF were selected and randomly divided into control group and observation group,with 47 cases in each group. Control group were treated with routine treatment,such as bed rest,oxygen inhalation,control of total body fluid in-take,routine anti-heart failure therapy and use of diuretic in 24 h. Based on the above treatment,observation group were treated with Torasemide injection with initial dose of 5-10 mg,qd,gradually increasing to 20 mg/d,maximal does of 40 mg/d. Both group re-ceived 7 days of continuous treatment. Clinical efficacies were observed in 2 groups as well as serum potassium and sodium,Scr,24 h urine volume and the rate ofⅠ-Ⅱgrade cardiac function before and after treatment. The occurrence of ADR was compared between 2 groups. RESULTS:The total effective rate of observation group was 61.70%,which was significantly higher than that of control group (46.81%),with statistical significance (P<0.05). There was no statistical significance in serum potassium and sodium and Scr between 2 groups before and after treatment(P>0.05). There was no statistical significance in 24 h urine volume and the rate ofⅠ-Ⅱgrade cardiac function between 2 groups before and after treatment(P>0.05);after treatment,24 h urine volume and the rate ofⅠ-Ⅱgrade cardiac function of 2 groups were increased significantly,the observation group was higher than the control group, with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS:Torasemide is effective for CHF,and can promote diuresis and the recovery of cardiac function with good safety.%目的：观察托拉塞米治疗慢性心力衰竭（CHF）患者的临床疗效及安全性。方法：选取CHF患者94例，按随机数字表法分为对照组和观察组，各47例。对照组患者采用卧床、吸氧、控制体液总入量、抗心力衰竭治疗及24 h内使用利尿剂等常规治疗；观察组患者在对照组基础上给予托拉塞米注射液初始剂量5～10 mg，qd，然后逐渐增加至20 mg/d，最大剂量为40 mg/d。两组患者均持续治疗7 d。观察两组患者临床疗效及治疗前后血钾、血钠、血肌酐（Scr）、24 h尿量及心功能Ⅰ～Ⅱ级率，并比较两组患者不良反应发生情况。结果：观察组患者总有效率为61.70％，显著高于对照组的46.81％，差异有统计学意义（P＜0.05）。两组患者治疗前后血钾、血钠及Scr水平比较，差异均无统计学意义（P＞0.05）。两组患者治疗前24 h尿量及心功能Ⅰ～Ⅱ级率比较，差异无统计学意义（P＞0.05）；两组患者治疗后24 h尿量及心功能Ⅰ～Ⅱ级率均显著升高，且观察组明显高于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应均较轻微，且发生率比较，差异无统计学意义（P＞0.05）。结论：托拉塞米治疗CHF疗效显著，能明显利尿并促进患者心功能恢复，且安全性较好。